References
- Garinet S, Laurent-Puig P, Blons H, Oudart J-B. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018; 7(6):144.
- Rodak O, Peris-Diaz MD, Olbromski M, Podhorska-Okolow M, Dziegiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers. 2021; 13(18):4705.
- Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18:1454–66.
- Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2):113–25.
- Salihefendić L, Pećar D, Konjhodžić R. Validation of CRC and NSCLC somatic mutations detected with NGS using ddPCR. Genetics & Applications. 2019; 3(1):71–6.
- Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013; 31:1070–80.
- Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240–7.
- Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med. 2005; 2(3):73.
- Cunha Santos G, Shepherd FA, Tsao MS. EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011; 6(1):49–69.
- Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019; 79(4):689–98.
- Rodriguez J, Avila J, Rolfo C, Ruiz-Patino A, Russo A, Ricaurte L et al. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021; 9(1):89–110.
- Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472–484.
- Droplet DigitalTM PCR Applications Guide (lab handbook). Hercules, California: Bio-Rad Laboratories Inc ; 2017.
- QIAamp® Circulating Nucleic Acid Handbook. Hilden, Germany: Qiagen, 2019.
- QIAvac 24 Plus Handbook (lab handbook). Hilden, Germany: Qiagen, 2010.
- Qubit® dsDNA HS Assay Kits (lab handbook). Carlsbad, California: Life Technologies, 2015.
- ddPCRTM EGFR T790M Screening Kit (lab handbook). Hercules, California: Bio-Rad Laboratories Inc ; 2016.
- Kim Y, Shin S, Lee KA. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy. Cancer Cell Int. 2021; 21(50).
- Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thorac Cancer. 2019; 10(10):1879–1884.
- Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med. 2005; 352(8): 786–92.
- Wang W, Song Z, Zhang Y. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Medicine. 2016; 6(1): 154–162.
- Yoon HJ, Lee HY, Lee KS, Choi, Y-L, Ahn M-J, Park K et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012; 265(3): 939–948.
- Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014; 86(2):170–3.
- Silveira C, Sousa AC, Janeiro A, Malveiro S, Teixeira E, Brysch E et al. Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR. Transl Lung Cancer Res, 2021; 10(3): 1200–1208.
- Jung A, Kirchner T. Liquid Biopsy in Tumor Genetic Diagnosis. Deutsches Arzteblatt international, 2018; 115(10): 169–174.
- Chan KCA, Jiang PY, Zheng YWL, Liao GJW, Sun H, Wong J et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem, 2013; 59(1): 211–24.
- Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Scientific Reports, 2016; 6,20913.